Karin Travers

2.7k total citations · 1 hit paper
34 papers, 1.9k citations indexed

About

Karin Travers is a scholar working on Infectious Diseases, Virology and Oncology. According to data from OpenAlex, Karin Travers has authored 34 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 8 papers in Virology and 6 papers in Oncology. Recurrent topics in Karin Travers's work include HIV Research and Treatment (8 papers), HIV/AIDS Research and Interventions (8 papers) and PARP inhibition in cancer therapy (4 papers). Karin Travers is often cited by papers focused on HIV Research and Treatment (8 papers), HIV/AIDS Research and Interventions (8 papers) and PARP inhibition in cancer therapy (4 papers). Karin Travers collaborates with scholars based in United States, Senegal and United Kingdom. Karin Travers's co-authors include Michael Barza, Phyllis J. Kanki, Max Essex, Souleymane Mboup, Aïssatou Guèye‐Ndiaye, Richard Marlink, Tidiane Siby, Ibrahima Ndoye, Ibou Thior and Jean‐Louis Sankalé and has published in prestigious journals such as Science, The Lancet and Clinical Infectious Diseases.

In The Last Decade

Karin Travers

33 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1

1994 432 citations Richard Marlink, Phyllis J. Kanki et al. profile →

Peers

Countries citing papers authored by Karin Travers

Since Specialization

Citations

This map shows the geographic impact of Karin Travers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Travers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Travers more than expected).

Fields of papers citing papers by Karin Travers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Travers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Travers. The network helps show where Karin Travers may publish in the future.

Co-authorship network of co-authors of Karin Travers

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Travers. A scholar is included among the top collaborators of Karin Travers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Travers. Karin Travers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Opportunities for tuberculosis elimination in the Canadian Arctic: cost-effectiveness of community-wide screening in a remote Arctic community 2024 ·The Lancet Regional Health - Americas ·Alice Zwerling, (unknown), (unknown), (unknown), Karin Travers, (unknown), (unknown), (unknown), (unknown), Jean Allen, Mike Patterson, Gonzalo G. Alvarez	2
2	366 Feasibility study of a network meta-analysis and unanchored population-adjusted indirect treatment comparison of niraparib, olaparib, and bevacizumab as maintenance therapies in patients with newly diagnosed advanced ovarian cancer 2020 ·Domenica Lorusso, (unknown), Jean Hamilton, Yevgeniy Samyshkin, Karin Travers, (unknown), Robert L. Coleman	1
3	Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy 2019 ·Journal of Comparative Effectiveness Research ·Kurt Neeser, William M. O’Neil, Lee Stern, B. Harrow, Karin Travers	2
4	The Effectiveness and Value of Palliative Care in the Outpatient Setting 2017 ·JAMA Internal Medicine ·(unknown), Daniel A. Ollendorf, Karin Travers	11
5	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation 2016 ·Leukemia & lymphoma ·Katja Weisel, Chantal Doyen, Meletios Α. Dimopoulos, (unknown), Juan José Lahuerta, Amber Martin, Karin Travers, Eric Druyts, (unknown), Niels Abildgaard, Jin Lu, Jan Van Droogenbroeck, Catarina Geraldes, Mario Petrini, Laurent Voillat, Éric Voog, Thierry Façon	32
6	P1‐147: A PROSPECTIVE, SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSES TO EVALUATE GLOBAL AND REGIONAL BRAIN VOLUMES BY STRUCTURAL MRI AS BIOMARKERS OF ALZHEIMER'S DISEASE (AD) PROGRESSION 2014 ·Alzheimer s & Dementia ·Enchi Liu, Ajibade Ashaye, Karin Travers, (unknown), (unknown), Gian Luca Di Tanna, Bradley T. Wyman, Kevin Booth, Scot Styren, Robert Brashear, Steven Einstein, Gerald Novak	0
7	Burden and management of chronic kidney disease in Japan: systematic review of the literature 2013 ·International Journal of Nephrology and Renovascular Disease ·Karin Travers, Amber Martin, (unknown), Kristina S. Boye, Lauren J. Lee	19
8	Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey 2013 ·ClinicoEconomics and Outcomes Research ·(unknown), Karin Travers, (unknown), (unknown), (unknown)	11
9	Mortality and Survival in Inoperable or Residual/Recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Systematic Literature Review 2013 ·Value in Health ·Michael Byrnes, Ajibade Ashaye, Ike Iheanacho, Karin Travers, Mirko Sikirica	1
10	Major depressive disorder in Africa and the Middle East: a systematic literature review 2013 ·Expert Review of Pharmacoeconomics & Outcomes Research ·Karin Travers, (unknown), (unknown), (unknown)	10
11	Validation of the BacT/ALERT(R) 3D System for Rapid Sterility Testing of Biopharmaceutical Samples 2012 ·PDA Journal of Pharmaceutical Science and Technology ·Luis Jiménez, Neerja Rana, John Amalraj, Kimberly Walker, Karin Travers	16
12	PIN11 The Impact of Directly Observed Therapy (DOT) in Patients with Tuberculosis 2011 ·Value in Health ·(unknown), Karin Travers, Anupama Kalsekar, Leah Kleinman	1
13	Humanistic and economic burden of generalized anxiety disorder in North America and Europe 2011 ·Journal of Affective Disorders ·Dennis A. Revicki, Karin Travers, Kathleen W. Wyrwich, Henrik Svedsäter, Julie Locklear, (unknown), David V. Sheehan, Stuart Montgomery	116
14	Morbidity of Infections Caused by Antimicrobial‐Resistant Bacteria 2002 ·Clinical Infectious Diseases ·Karin Travers, Michael Barza	144
15	Review of Assessments of the Human Health Risk Associated with the Use of Antimicrobial Agents in Agriculture 2002 ·Clinical Infectious Diseases ·John C. Bailar, Karin Travers	26
16	Interaction with Human Immunodeficiency Virus (HIV) Type 2 Predicts HIV Type 1 Genotype 2000 ·Virology ·Abdoulaye Dieng Sarr, Jean-Louis Sankalé, Donald J. Hamel, Karin Travers, Aïssatou Guèye‐Ndiaye, Max Essex, Souleymane Mboup, Phyllis Kanki	12
17	Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV‐1 and HIV‐2 1999 ·The Journal of Infectious Diseases ·Stephen J. Popper, Abdoulaye Dieng Sarr, Karin Travers, Aïssatou Guèye‐Ndiaye, Souleymane Mboup, Max Essex, Phyllis J. Kanki	172
18	Clusters of Lymphoma in Ferrets 1996 ·Cancer Investigation ·Susan E. Erdman, Phyllis J. Kanki, Frances M. Moore, Susan A. Brown, (unknown), Keith Mikule, Karin Travers, Stephen F. Badylak, James G. Fox	23
19	Slower heterosexual spread of HIV-2 than HIV-1 1994 ·The Lancet ·Phyllis J. Kanki, Karin Travers, Richard Marlink, Max Essex, (unknown), Aïssatou Guèye‐Ndiaye, Tidiane Siby, Ibou Thior, Jean‐Louis Sankalé, Chang‐Chi Hsieh, Mauricio Hernández-Ávila, Ibrahima Ndoye	259
20	Prevalence and Risk Determinants of Human Immunodeficiency Virus Type 2 (HIV-2) and Human Immunodeficiency Virus Type 1 (HIV-1) in West African Female Prostitutes 1992 ·American Journal of Epidemiology ·Phyllis J. Kanki, Souleymane Mboup, Richard Marlink, Karin Travers, Chang‐Chi Hsieh, (unknown), Cheikh Saad Bouh Boye, (unknown), Christl A. Donnelly, Wendy M. Leisenring, Tidiane Siby, Ibou Thior, M. Dia, (unknown), Ibrahima N’Doye, Max Essex	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact